Frontier Investment Mgmt Co. Has $315,000 Holdings in Novartis AG (NVS)
Frontier Investment Mgmt Co. lowered its position in Novartis AG (NYSE:NVS) by 19.8% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 3,752 shares of the company’s stock after selling 927 shares during the period. Frontier Investment Mgmt Co.’s holdings in Novartis were worth $315,000 at the end of the most recent reporting period.
Other large investors have also recently bought and sold shares of the company. Cetera Investment Advisers bought a new position in shares of Novartis in the second quarter valued at approximately $241,000. Bartlett & Co. LLC raised its stake in shares of Novartis by 1.6% in the third quarter. Bartlett & Co. LLC now owns 473,081 shares of the company’s stock valued at $40,614,000 after acquiring an additional 7,249 shares during the last quarter. Capital Bank & Trust Co raised its stake in shares of Novartis by 5.5% in the third quarter. Capital Bank & Trust Co now owns 138,207 shares of the company’s stock valued at $11,865,000 after acquiring an additional 7,201 shares during the last quarter. Atlantic Trust Group LLC raised its stake in shares of Novartis by 54.2% in the third quarter. Atlantic Trust Group LLC now owns 72,427 shares of the company’s stock valued at $6,218,000 after acquiring an additional 25,452 shares during the last quarter. Finally, Rothschild Investment Corp IL raised its stake in shares of Novartis by 26.9% in the fourth quarter. Rothschild Investment Corp IL now owns 26,200 shares of the company’s stock valued at $2,200,000 after acquiring an additional 5,550 shares during the last quarter. Institutional investors own 10.80% of the company’s stock.
Shares of Novartis AG (NYSE NVS) traded down $0.03 during trading on Wednesday, hitting $82.24. 1,580,000 shares of the company were exchanged, compared to its average volume of 1,820,000. The company has a current ratio of 1.21, a quick ratio of 0.91 and a debt-to-equity ratio of 0.31. The firm has a market capitalization of $214,570.00, a price-to-earnings ratio of 25.07, a P/E/G ratio of 1.93 and a beta of 0.78. Novartis AG has a fifty-two week low of $72.67 and a fifty-two week high of $94.19.
A number of research analysts have recently issued reports on NVS shares. Nord/LB reiterated a “neutral” rating on shares of Novartis in a research note on Tuesday, January 2nd. JPMorgan Chase & Co. reiterated a “neutral” rating on shares of Novartis in a research note on Thursday, January 18th. UBS Group reissued a “neutral” rating on shares of Novartis in a report on Monday, January 15th. Zacks Investment Research lowered shares of Novartis from a “hold” rating to a “sell” rating in a report on Tuesday, January 2nd. Finally, Bank of America lowered shares of Novartis from a “neutral” rating to an “underperform” rating in a report on Wednesday, December 6th. Four research analysts have rated the stock with a sell rating, eight have issued a hold rating and one has issued a buy rating to the company. The stock currently has an average rating of “Hold” and a consensus target price of $87.51.
TRADEMARK VIOLATION WARNING: This piece was reported by Marea Informative and is the property of of Marea Informative. If you are accessing this piece on another site, it was copied illegally and republished in violation of United States and international copyright and trademark law. The original version of this piece can be accessed at https://www.mareainformativa.com/2018/03/14/novartis-ag-nvs-shares-sold-by-frontier-investment-mgmt-co-updated-updated-updated.html.
Novartis Company Profile
Novartis AG is a holding company, which provides healthcare solutions. The Company is engaged in the research, development, manufacturing and marketing of a range of healthcare products led by pharmaceuticals. The Company’s segments include Innovative Medicines, Sandoz, Alcon and Corporate activities.
Receive News & Ratings for Novartis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novartis and related companies with MarketBeat.com's FREE daily email newsletter.